Retatrutide Phase 3 Trials: What's Coming and When

Retatrutide's Phase 3 program comprises multiple large, randomized, placebo-controlled trials designed to confirm the efficacy and characterize the safety profile in diverse populations. The program includes trials in subjects with obesity, subjects with type 2 diabetes and obesity, and potentially trials examining cardiovascular outcomes. These trials are collectively known by the TRIUMPH identifier (Trial Retatrutide for Metabolic Effects and Weight Management in Patients with Obesity and Insulin Resistance, or similar naming), with different trials designated TRIUMPH-1, TRIUMPH-2, etc., by trial site or indication.

Each Phase 3 trial enrolls several thousand subjects (typically 3,000-8,000 per trial), followed for 1-2 years. This large population size and extended duration allow researchers to detect rare side effects, assess long-term efficacy and safety, and examine outcomes across diverse subgroups. The design is more representative of real-world populations than Phase 2 trials, improving generalizability of findings.

Phase 3 trials for retatrutide are being conducted globally, with enrollment centers in North America, Europe, Asia, and other regions. This geographic diversity ensures that trial results are relevant to diverse populations with varying genetic backgrounds, healthcare systems, and dietary environments. As of 2026, major Phase 3 trials have completed enrollment or are in the final enrollment phases. Some trials have already begun to complete subject follow-up, while others are in the mid-stages of the study period.

The geographic diversity also reflects regulatory requirements: the FDA, EMA (European Medicines Agency), and other regulatory bodies typically expect Phase 3 data from populations representative of the intended market. Trials enrolling predominantly one geographic region may not be sufficient to support approval in other regions.

The main Phase 3 trials typically include subjects with BMI ≥ 27-30 kg/m² with weight-related comorbidities or BMI ≥ 30 kg/m² without comorbidities, mirroring the population likely to receive retatrutide in clinical practice. Some trials specifically enroll subjects with type 2 diabetes to assess efficacy and safety in this high-risk population. Cardiovascular outcome trials, which are longer and more costly, may be initiated if Phase 3 results suggest potential cardiovascular benefit, as these trials are necessary to support cardiovascular indication claims.

The primary efficacy endpoint in most Phase 3 trials is weight loss, measured as the percent change in body weight from baseline to a specified timepoint (typically 1-2 years). Secondary endpoints include HbA1c change (in trials enrolling subjects with diabetes), lipid changes, and body composition. Safety is assessed comprehensively through adverse event monitoring, laboratory values, and vital signs. Quality of life and functional outcomes may also be assessed.

Based on publicly available information about Phase 3 trial enrollment and duration, results from the main Phase 3 trials are expected to become available (in the form of conference presentations or data releases) in late 2026 and into 2027. FDA advisory committees may review retatrutide data in late 2026 or early 2027, with regulatory decisions potentially coming in 2027 or later, depending on trial completion and data quality.

However, regulatory timelines can be variable. If data are particularly robust and there are no unexpected safety signals, approval might come sooner. If additional data or follow-up studies are requested, approval could be delayed. Pharmaceutical companies sometimes seek priority or accelerated review designations if a drug addresses an unmet medical need, which could accelerate timelines. The specific timeline for retatrutide will become clearer as Phase 3 trials progress and results are released.

Phase 3 trials will provide definitive data on retatrutide's weight-loss efficacy compared to placebo and potentially compared to active comparators (e.g., tirzepatide or other agents), clarify the long-term safety profile and the frequency of rare adverse events, assess metabolic outcomes (HbA1c, lipids) in diverse populations, and examine whether early Phase 2 benefits are sustained over 1-2 years of treatment.

Additionally, Phase 3 will assess heterogeneity of response: do all populations achieve similar weight loss, or are there subgroups (based on age, baseline BMI, baseline metabolism, genetic factors) that respond better or worse? This information is important for clinicians and patients to set realistic expectations. The durability of weight loss after stopping treatment, assessed in some trials through post-treatment follow-up phases, will also inform understanding of retatrutide's long-term effects.